Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. Kezar Life Sciences recently acquired a new stake in shares of Kezar Life Sciences, Inc. and is backed by a number of other hedge funds. The California State Teachers Retirement System, BNP Paribas Arbitrage SNC, State Street Corp, Public Employees Retirement System of Ohio, and Jacobs Levy Equity Management Inc. all hold significant stakes in Kezar Life Sciences. Additionally, the company’s share price on NASDAQ ranges from a low of $3.96 to a high of $9.17, with a market capitalization of $237.18 million.
In the third quarter, Robeco Institutional Asset Management B.V. acquired a new stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR), according to its most recent disclosure. This acquisition was accompanied by several other hedge funds that bought and sold shares of the company, including California State Teachers Retirement System, BNP Paribas Arbitrage SNC, State Street Corp, Public Employees Retirement System of Ohio, and Jacobs Levy Equity Management Inc.
As of the third quarter, the California State Teachers Retirement System owns 59,768 shares of Kezar Life Sciences valued at $515,000, after buying an additional 3,744 shares in the last quarter. BNP Paribas Arbitrage SNC also increased its stake in Kezar Life Sciences by 595.1% to 114,545 shares valued at $986,000 after buying an additional 98,066 shares in the last quarter. State Street Corp increased its stake in the company by 381.3% to 3,537,701 shares valued at $30,460,000 after buying an additional 2,802,611 shares in the last quarter.
Furthermore, Public Employees Retirement System of Ohio bought a new stake in Kezar Life Sciences, valued at about $167,000, while Jacobs Levy Equity Management Inc. purchased a new stake in Kezar Life Sciences, valued at about $683,000. Currently, 84.03% of the stock is owned by hedge funds and other institutional investors.
In other news, on Thursday, January 12th, major shareholder Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock at an average price of $6.77, for a total value of $33,850.00. Following the transaction, the insider now owns 5,881,078 shares in the company, valued at $39,814,898.06. Over the last quarter, insiders have sold 248,276 shares of company stock worth $1,708,683. Insiders own 7.80% of the company’s stock.
Analyst Ratings Changes
William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, March 15th. HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of Kezar Life Sciences in a report on Thursday, March 16th. Finally, Wells Fargo & Company dropped their target price on Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, January 3rd.
Kezar Life Sciences Price Performance
Kezar Life Sciences (KZR) has been publicly traded on NASDAQ since June 2018. The company’s share price has ranged from a low of $3.96 to a high of $9.17. As of the time of this writing, the company’s share price is $6.84.
Kezar Life Sciences Overview
Kezar Life Sciences, Inc. (NASDAQ:KZR) opened at $3.35 on Friday, with a 50-day moving average of $6.06 and a 200-day moving average of $7.12. The company has a market capitalization of $237.18 million, a price-to-earnings ratio of -3.32, and a beta of 0.25. Kezar Life Sciences has a fifty-two week low of $3.33 and a fifty-two week high of $18.52. The company’s product pipeline includes KZR-616, KZR-261, and KZR-TBD, which are small molecule therapeutics for the treatment of autoimmunity and cancer. The company was founded by John Fowler and Christopher J. Kirk in 2015 and is based in South San Francisco, California.
Kezar Life Sciences Profile
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is engaged in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company’s product pipeline includes KZR-616, a first-in-class immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases; KZR-261, a novel immune modulator targeting systemic lupus erythematosus; and KZR-TBD, a targeted immunotherapeutic approach to cancer treatment. Kezar Life Sciences is committed to developing innovative therapies that address significant unmet medical needs.
See Also
Investors interested in Kezar Life Sciences can receive daily news and analysts’ ratings by signing up for MarketBeat.com’s FREE daily email newsletter.
Don’t miss interesting posts on Famousbio
